MedTrace Logo

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

NCT03797625 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-07-23

No results posted yet for this study

Summary

The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

Conditions

Interventions

DRUG

Irinotecan

60mg/m2，D1，8

DRUG

DDP

60mg/m2，D1

DRUG

Endostar

15mg/d，d1-d7 civ

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • chang jian hua, PD · PI

  • wang hui jie, doctor · SUBI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-04
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03797625 on ClinicalTrials.gov